Clorgyline-mediated reversal of neurological deficits in a Complexin 2 knockout mouse

  • Dervila Glynn
  • , Helen E. Gibson
  • , Michael K. Harte
  • , Kerstin Reim
  • , Susan Jones
  • , Gavin P. Reynolds
  • , A. Jennifer Morton

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Complexin 2 is a protein modulator of neurotransmitter release that is downregulated in humans suffering from depression, animal models of depression and neurological disorders such as Huntington's disease in which depression is a major symptom. Although complexin 2 knockout (Cplx2-/-) mice are overtly normal, they show significant abnormalities in cognitive function and synaptic plasticity. Here we show that Cplx2-/- mice also have disturbances in emotional behaviours that include abnormal social interactions and depressive-like behaviour. Since neurotransmitter deficiencies are thought to underlie depression, we examined neurotransmitter levels in Cplx2-/- mice and found a significant decrease in levels of noradrenaline and the serotonin metabolite 5-hydroxyindoleacetic acid in the hippocampus. Chronic treatment with clorgyline, an irreversible inhibitor of monoamine oxidase A, restored hippocampal noradrenaline to normal levels (from 60 to 97% of vehicle-treated Cplx2+/+mice, P <0.001), and reversed the behavioural deficits seen in Cplx2-/- mice. For example, clorgyline-treated Cplx2-/- mice spent significantly more time interacting with a novel visitor mouse compared with vehicle-treated Cplx2-/- mice in the social recognition test (34 compared with 13%, P <0.01). We were also able to reverse the selective deficit seen in mossy fibre-long-term potentiation (MF-LTP) in Cplx2-/- mice using the noradrenergic agonist isoprenaline. Pre-treatment with isoprenaline in vitro increased MF-LTP by 125% (P <0.001), thus restoring it to control levels. Our data strongly support the idea that complexin 2 is a key player in normal neurological function, and that downregulation of complexin 2 could lead to changes in neurotransmitter release sufficient to cause significant behavioural abnormalities such as depression. © The Author 2010. Published by Oxford University Press. All rights reserved.
    Original languageEnglish
    Article numberddq252
    Pages (from-to)3402-3412
    Number of pages10
    JournalHuman Molecular Genetics
    Volume19
    Issue number17
    DOIs
    Publication statusPublished - 28 Jun 2010

    Fingerprint

    Dive into the research topics of 'Clorgyline-mediated reversal of neurological deficits in a Complexin 2 knockout mouse'. Together they form a unique fingerprint.

    Cite this